KZIA
Kazia Therapeutics Limited
NASDAQ · Healthcare · Biotechnology · AU
$12.31
+1.23%Next report
Analyst consensus
- Next report date
- Sep 4, 2026
- EPS estimate
- -$0.61
- Revenue estimate
- $488.9K
Latest reported
- Last report date
- Nov 19, 2024
- EPS actual
- -$0.04
- EPS estimate
- -$15
- Revenue actual
- $1.7M
- Revenue estimate
- $100.0K
Track record
Trailing twelve quarters
- EPS beats (12Q)
- 5
- EPS misses (12Q)
- 0
- EPS in line (12Q)
- 0
- Avg surprise (4Q)
- +99.5%
- Revenue beats (12Q)
- 1
Analyst ratings
Sell-side consensus
- Consensus
- Buy
- Price target
- $34
- PT range
- $29 – $40
- Analysts
- 3
3 Buy0 Hold0 Sell
Reported results against consensus at the time of each report · Surprise is computed from the estimate on record · Data as of Sep 4, 2026